Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection von Browne, Sarah K., Zaman, Rifat, Sampaio, Elizabeth P., Jutivorakool, Kamonwan, Rosen, Lindsey B., Ding, Li, Pancholi, Minjal J., Yang, Lauren M., Priel, Debra Long, Uzel, Gulbu, Freeman, Alexandra F., Hayes, Carlton E., Baxter, Roger, Cohen, Stuart H., Holland, Steven M.

Volltext

Phase II study of cixutumumab (IMC-A12) in thymic malignancies von Rajan, Arun, Riely, Gregory J., Carter, Corey Allan, Thomas, Anish, Khozin, Sean, Bergagnini, Isabella, Berman, Arlene W, Scepura, Barbara, Szabo, Eva, Lee, Min-Jung, Trepel, Jane B., Browne, Sarah K, Pancholi, Minjal J, Cao, Liang, Chen, Helen X., Giaccone, Giuseppe

Volltext